J. Mark Sloan, MD

Associate Professor, Medicine

J. Sloan
617.638.7520
820 Harrison Ave

Biography

Factotum hematologist at Boston Medical Center and Associate Professor at Boston University School of Medicine. Program director for the hematology/oncology fellowship at Boston University.I see patients with a variety of benign and malignant blood disorders. I have particular research interests in AL Amyloidosis, HTLV-1 associated leukemia/lymphoma (ATLL), and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Exceptional Care Without Exception.

Other Positions

  • Member, BU-BMC Cancer Center, Boston University
  • Member, Amyloidosis Center, Boston University
  • Member, Evans Center for Interdisciplinary Biomedical Research, Boston University

Education

  • Yale University School of Medicine, MD
  • Harverford College, BS

Publications

  • Published on 5/27/2021

    Milrod CJ, Blevins F, Hughes D, Lerner A, Sarosiek S, Sanchorawala V, Sloan JM. Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs. Blood. 2021 May 27; 137(21):2987-2989. PMID: 33728443.

    Read at: PubMed
  • Published on 3/1/2021

    Kaufman AR, Quillen K, Distefano AG, Sloan JM. Nonsecretory Recurrence of Multiple Myeloma Presenting as Sixth Nerve Palsy Secondary to Clival Plasmacytoma. J Neuroophthalmol. 2021 03 01; 41(1):e77-e78. PMID: 32235225.

    Read at: PubMed
  • Published on 1/6/2021

    Hughes DM, DeMari S, Hassan H, Sanchorawala V, Sloan JM. Safety, Tolerability, and Efficacy of Selinexor in a Patient With Relapsed Light Chain (AL) Amyloidosis. Clin Lymphoma Myeloma Leuk. 2021 May; 21(5):e460-e463. PMID: 33716055.

    Read at: PubMed
  • Published on 9/1/2020

    Sarosiek S, Zheng L, Sloan JM, Quillen K, Brauneis D, Sanchorawala V. Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis. Blood Cancer J. 2020 09 01; 10(8):88. PMID: 32873776.

    Read at: PubMed
  • Published on 7/31/2020

    Szalat R, Sarosiek S, Havasi A, Brauneis D, Sloan JM, Sanchorawala V. Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis. Leukemia. 2021 03; 35(3):916-919. PMID: 32737434.

    Read at: PubMed
  • Published on 7/3/2020

    Gupta VK, Strykowski R, Scarpato B, Lawrence R, Khan SL, Patel J, Nouraie SM, Cohen RT, Sloan JM, Klings ES. The effect of anticoagulant choice on venous thromboembolism recurrence and bleeding in sickle cell disease. Am J Hematol. 2020 Jul 03. PMID: 32619024.

    Read at: PubMed
  • Published on 6/19/2020

    Dumas B, Yameen H, Sarosiek S, Sloan JM, Sanchorawala V. Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen. Amyloid. 2020 Dec; 27(4):244-249. PMID: 32551974.

    Read at: PubMed
  • Published on 4/30/2020

    Sanchorawala V, Sarosiek S, Schulman A, Mistark M, Migre ME, Cruz R, Sloan JM, Brauneis D, Shelton AC. Safety, tolerability, and response rates of daratumumab in relapsed AL amyloidosis: results of a phase 2 study. Blood. 2020 04 30; 135(18):1541-1547. PMID: 31978210.

    Read at: PubMed
  • Published on 3/9/2020

    Angel-Korman A, Stern L, Angel Y, Sarosiek S, Menn-Josephy H, Francis J, Ghai S, Sloan JM, Sanchorawala V, Havasi A. The Role of Kidney Transplantation in Monoclonal Ig Deposition Disease. Kidney Int Rep. 2020 Apr; 5(4):485-493. PMID: 32274452.

    Read at: PubMed
  • Published on 11/26/2019

    Staron A, Kataria Y, Murray DL, Sloan JM, Sanchorawala V. Systemic AL amyloidosis with an undetectable plasma cell dyscrasia: A zebra without stripes. Am J Hematol. 2020 02; 95(2):E45-E48. PMID: 31736101.

    Read at: PubMed

View 56 more publications: View full profile at BUMC

View all profiles